GLP-1 Market
LLY $1150.99 ▼ -1.6% NVO $38.17 ▼ -3.1% PFE $28.18 ▲ +0.9% VKTX $41.65 ▲ +2.0% KLRA $13.13 ▲ +2.7% GPCR $35.95 ▼ -2.6% RHHBY $55.06 ▼ -0.9%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Daratumumab

Company
Janssen Research & Development, LLC
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
114 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

114 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 24, 2026

Find a Clinical Trial Near Me

See recruiting studies for Daratumumab and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT02343042

    Selinexor and Backbone Treatments of Multiple Myeloma Patients

    Not yet reported, Not yet reported Karyopharm Therapeutics Inc 300 participants Est. completion 2027-04 25 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT03899155

    Pan Tumor Rollover Study

    Not yet reported Bristol-Myers Squibb 1500 participants Est. completion 2029-08-25 399 sites Stand-alone
    Other conditions: Cancer
    View official trial listing →
  • Recruiting NCT NCT03937635

    Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

    Not yet reported ECOG-ACRIN Cancer Research Group 288 participants Est. completion 2029-12-31 748 sites Stand-alone
    Other conditions: Smoldering Plasma Cell Myeloma
    View official trial listing →
  • Recruiting NCT NCT04068597

    Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

    Not yet reported, Not yet reported CellCentric Ltd. 250 participants Est. completion 2027-03-31 39 sites Stand-alone
    Other conditions: Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT04139304

    A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

    Not yet reported AIDS Malignancy Consortium 15 participants Est. completion 2030-07 8 sites Stand-alone
    Other conditions: Plasmablastic Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT04513639

    The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

    Not yet reported, Not yet reported Oslo University Hospital 176 participants Est. completion 2032-06-01 13 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT04566328

    Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

    Not yet reported ECOG-ACRIN Cancer Research Group 1450 participants Est. completion 2027-12-31 647 sites Stand-alone
    Other conditions: Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
    View official trial listing →
  • Recruiting NCT NCT04643002

    Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

    Not yet reported, Not yet reported Sanofi 258 participants Est. completion 2028-04-20 26 sites
    Other conditions: Plasma Cell Myeloma Refractory
    View official trial listing →
  • Recruiting NCT NCT04661137

    A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

    Not yet reported Hackensack Meridian Health 96 participants Est. completion 2028-02 2 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT04910568

    A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported Genentech, Inc. 186 participants Est. completion 2028-12-21 34 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT04915248

    Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

    Not yet reported Fondazione Italiana Linfomi - ETS 28 participants Est. completion 2027-07-01 18 sites Stand-alone
    Other conditions: Plasmablastic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT04972942

    Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

    Not yet reported New York Medical College 30 participants Est. completion 2028-09 16 sites
    Other conditions: T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT04973605

    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

    Not yet reported, Not yet reported BeOne Medicines 246 participants Est. completion 2026-11 78 sites Stand-alone
    Other conditions: Relapsed/Refractory Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT04991103

    Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

    Not yet reported University of Alabama at Birmingham 40 participants Est. completion 2028-08-27 1 site Stand-alone
    Other conditions: Multiple Myeloma, Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT05020236

    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

    Not yet reported Pfizer 893 participants Est. completion 2027-05-31 237 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05137054

    A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

    Not yet reported Regeneron Pharmaceuticals 317 participants Est. completion 2032-03-24 42 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05203003

    Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.

    Assistance Publique - Hôpitaux de Paris 260 participants Est. completion 2028-12 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05289687

    Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

    Not yet reported Eastern Cooperative Oncology Group 20 participants Est. completion 2027-06-30 1 site Stand-alone
    Other conditions: T-cell Acute Lymphoblastic Leukemia
    View official trial listing →
  • Recruiting NCT NCT05363111

    Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

    Not yet reported City of Hope Medical Center 15 participants Est. completion 2027-03-23 1 site Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Recruiting NCT NCT05552222

    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 1590 participants Est. completion 2033-10-28 270 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05561387

    Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

    Not yet reported SWOG Cancer Research Network 510 participants Est. completion 2031-05-30 397 sites Stand-alone
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Recruiting NCT NCT05572229

    Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma

    Not yet reported University Hospital, Lille 74 participants Est. completion 2030-09 29 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05623020

    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

    Not yet reported Pfizer 1116 participants Est. completion 2033-10-03 139 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05671757

    Daratumumab in Primary Antiphospholipid Syndrome

    Not yet reported, Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 22 participants Est. completion 2027-03 8 sites Stand-alone
    Other conditions: Autoimmune Disorders
    View official trial listing →
  • Recruiting NCT NCT05695508

    GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

    Not yet reported University of Heidelberg Medical Center 160 participants Est. completion 2029-09-15 11 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05749276

    Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)

    Not yet reported Nantes University Hospital 12 participants Est. completion 2028-08-06 1 site Stand-alone
    Other conditions: Adult Patients With Adverse Risk Acute Myeloblastic Leukemia
    View official trial listing →
  • Recruiting NCT NCT05849740

    An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 25 participants Est. completion 2027-10-31 1 site Stand-alone
    Other conditions: Acquired Hemophilia
    View official trial listing →
  • Recruiting NCT NCT05888870

    ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 50 participants Est. completion 2026-12-01 1 site Stand-alone
    Other conditions: Hemophilia A With Inhibitor
    View official trial listing →
  • Recruiting NCT NCT05896228

    Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

    Not yet reported Benjamin T Diamond, MD 30 participants Est. completion 2031-03-01 1 site Stand-alone
    Other conditions: Refractory Multiple Myeloma, Relapsed Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05898646

    Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

    Not yet reported Mayo Clinic 96 participants Est. completion 2026-11-30 2 sites Stand-alone
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT05907759

    Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

    Not yet reported National Cancer Institute (NCI) 28 participants Est. completion 2035-12-01 1 site Stand-alone
    Other conditions: Lymphoma, Primary Effusion
    View official trial listing →
  • Recruiting NCT NCT06022939

    Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

    Not yet reported SWOG Cancer Research Network 338 participants Est. completion 2030-10-29 117 sites Stand-alone
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT06083922

    A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

    Not yet reported Memorial Sloan Kettering Cancer Center 20 participants Est. completion 2026-10 11 sites Stand-alone
    Other conditions: Multiple Myeloma, Monoclonal Gammopathy of Renal Significance
    View official trial listing →
  • Recruiting NCT NCT06100237

    Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

    Not yet reported Carl Ola Landgren, MD, PhD 50 participants Est. completion 2029-12-31 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06107738

    Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

    Not yet reported Barbara Ann Karmanos Cancer Institute 60 participants Est. completion 2028-12-31 2 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06119685

    IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

    Not yet reported, Not yet reported Indapta Therapeutics, INC. 128 participants Est. completion 2029-12-31 12 sites Stand-alone
    Other conditions: NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06140966

    Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

    Not yet reported Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 54 participants Est. completion 2027-10-20 1 site Stand-alone
    Other conditions: Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06142396

    Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

    Not yet reported Augusta University 30 participants Est. completion 2027-11-01 1 site Stand-alone
    Other conditions: Multiple Myeloma, Renal Failure
    View official trial listing →
  • Recruiting NCT NCT06158269

    DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 40 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06182774

    Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

    Not yet reported Canadian Cancer Trials Group 570 participants Est. completion 2032-07-31 29 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06187441

    FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)

    Not yet reported Stichting Hemato-Oncologie voor Volwassenen Nederland 599 participants Est. completion 2037-12 38 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06192979

    Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

    Not yet reported Jin Lu, MD 41 participants Est. completion 2027-03-31 7 sites
    Other conditions: Amyloidosis; Systemic, AL Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT06251076

    Plan Development for Giving Teclistamab in the Outpatient Setting

    Not yet reported University Health Network, Toronto 15 participants Est. completion 2026-10 1 site
    Other conditions: Multiple Myeloma, Relapsed Cancer, Refractory Cancer
    View official trial listing →
  • Recruiting NCT NCT06252792

    Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma

    FengYan Jin 50 participants Est. completion 2026-06-15 1 site
    Other conditions: Multiple Myeloma, First Relapse
    View official trial listing →
  • Recruiting NCT NCT06287944

    225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

    Not yet reported City of Hope Medical Center 15 participants Est. completion 2028-05-19 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Recruiting NCT NCT06356571

    A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

    Not yet reported Sanofi 64 participants Est. completion 2027-07-15 34 sites
    Other conditions: Plasma Cell Myeloma Refractory
    View official trial listing →
  • Recruiting NCT NCT06358638

    Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody

    Not yet reported Children's National Research Institute 12 participants Est. completion 2054-09 1 site Stand-alone
    Other conditions: Sickle Cell Disease
    View official trial listing →
  • Recruiting NCT NCT06376214

    Daratumumab for Patients With Light Chain Amyloidosis

    Not yet reported Nanjing University School of Medicine 100 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Light Chain (AL) Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT06398457

    Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 8 participants Est. completion 2027-03 1 site Stand-alone
    Other conditions: Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Acute Lymphoblastic Leukemia (ALL), Adult, Multiple Myeloma, Aplastic Anemia, Lymphoma, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Myeloid Leukemia, Myelofibrosis
    View official trial listing →
  • Recruiting NCT NCT06409702

    Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

    Not yet reported The First Affiliated Hospital of Soochow University 59 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Newly Diagnosed, High Risk, MRD, Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06418477

    Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD

    Not yet reported Peking University People's Hospital 20 participants Est. completion 2026-12-31 3 sites Stand-alone
    Other conditions: Monoclonal Gammopathy of Renal Significance
    View official trial listing →
  • Recruiting NCT NCT06464991

    A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

    Not yet reported Nanjing IASO Biotechnology Co., Ltd. 240 participants Est. completion 2030-12 28 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06477783

    Study on the Clinical Efficacy of Teclistamab

    Universitaire Ziekenhuizen KU Leuven 100 participants Est. completion 2027-09 17 sites
    Other conditions: Multiple Myeloma, Hematologic Diseases
    View official trial listing →
  • Recruiting NCT NCT06497738

    A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma

    The First Affiliated Hospital with Nanjing Medical University 112 participants Est. completion 2027-06-01 6 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06500884

    A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

    Not yet reported Janssen Research & Development, LLC 210 participants Est. completion 2030-05-30 38 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06505369

    Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

    Not yet reported North Estonia Medical Centre 50 participants Est. completion 2028-10 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06541860

    DAratumumab and REvlimid REfractory MM

    Fondazione IRCCS Policlinico San Matteo di Pavia 100 participants Est. completion 2028-08-21 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06615479

    A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

    Not yet reported Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 440 participants Est. completion 2032-06-22 141 sites Stand-alone
    Other conditions: Relapsed or Refractory Multiple Myeloma (RRMM)
    View official trial listing →
  • Recruiting NCT NCT06622005

    SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported Roswell Park Cancer Institute 15 participants Est. completion 2030-04-10 1 site Stand-alone
    Other conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06627309

    Rapid dFLC Response Predict CHR in AL Amyloidosis

    Peking University People's Hospital 50 participants Est. completion 2026-12-31 8 sites
    Other conditions: Systemic AL Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT06636552

    An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L

    Not yet reported Hellenic Society of Hematology 43 participants Est. completion 2029-01-05 7 sites
    Other conditions: Primary Plasma Cell Leukemia
    View official trial listing →
  • Recruiting NCT NCT06679101

    A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

    Not yet reported GlaxoSmithKline 520 participants Est. completion 2031-04-28 181 sites
    Other conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06697483

    Risk Stratification and MRD-driven Maintenance for MM After ASCT

    Not yet reported Peking University People's Hospital 100 participants Est. completion 2027-12-31 4 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06768489

    A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 240 participants Est. completion 2029-06-29 16 sites Stand-alone
    Other conditions: Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT06785415

    Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

    Not yet reported, Not yet reported Mayo Clinic 37 participants Est. completion 2031-04-01 1 site Stand-alone
    Other conditions: Recurrent Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06827860

    Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

    Not yet reported Larysa Sanchez 23 participants Est. completion 2028-01 1 site Stand-alone
    Other conditions: Multiple Myeloma in Relapse
    View official trial listing →
  • Recruiting NCT NCT06838962

    Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 30 participants Est. completion 2026-08 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia, Treatment
    View official trial listing →
  • Recruiting NCT NCT06867991

    Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis

    Not yet reported The First People's Hospital of Changzhou 200 participants Est. completion 2027-11-08 2 sites Stand-alone
    Other conditions: Anti-N-Methyl-D-Aspartate Receptor Encephalitis
    View official trial listing →
  • Recruiting NCT NCT06889948

    The Effect of Daratumumab in Patients With Monoclonal Gammopathy of Renal Significance (MGRS) in Finland

    Not yet reported Helsinki University Central Hospital 30 participants Est. completion 2027-06 1 site
    Other conditions: Kidney Failure, Paraproteinemias, Glomerulonephritis
    View official trial listing →
  • Recruiting NCT NCT06892522

    A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

    Not yet reported, Not yet reported AbbVie 602 participants Est. completion 2035-12 34 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06918002

    Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

    Not yet reported Intergroupe Francophone du Myelome 824 participants Est. completion 2036-05 64 sites Stand-alone
    Other conditions: Multiple Myeloma, Newly Diagnosed
    View official trial listing →
  • Recruiting NCT NCT06932562

    A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

    Not yet reported European Myeloma Network B.V. 1000 participants Est. completion 2036-12 59 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06948084

    Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

    Not yet reported National Cancer Institute (NCI) 80 participants Est. completion 2028-02-28 1 site Stand-alone
    Other conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06952478

    A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma

    Not yet reported Celltrion 486 participants Est. completion 2029-06-25 1 site Stand-alone
    Other conditions: Refractory or Relapsed Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06953960

    A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

    Not yet reported, Not yet reported AbbVie 325 participants Est. completion 2030-12 50 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06974786

    Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

    Not yet reported SCRI Development Innovations, LLC 100 participants Est. completion 2033-04 11 sites Stand-alone
    Other conditions: Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
    View official trial listing →
  • Recruiting NCT NCT07018050

    Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

    Not yet reported Qilu Pharmaceutical Co., Ltd. 160 participants Est. completion 2028-07 1 site Stand-alone
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07021677

    Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"

    Not yet reported Tata Memorial Centre 18 participants Est. completion 2026-08-28 1 site
    Other conditions: T Acute Lymphoblastic Leukemia
    View official trial listing →
  • Recruiting NCT NCT07045909

    Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

    Not yet reported PETHEMA Foundation 30 participants Est. completion 2030-03-31 10 sites Stand-alone
    Other conditions: De Novo Multiple Myeloma, Anitocabtagene Autoleucel
    View official trial listing →
  • Recruiting NCT NCT07063199

    Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 30 participants Est. completion 2026-08 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia, Treatment
    View official trial listing →
  • Recruiting NCT NCT07075510

    Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders

    Not yet reported, Not yet reported University of Maryland, Baltimore 30 participants Est. completion 2032-10-01 1 site Stand-alone
    Other conditions: Plasma Cell Disorder
    View official trial listing →
  • Recruiting NCT NCT07081126

    Daratumumab for Late Antibody-Mediated Rejection

    Not yet reported University Hospital, Martin 20 participants Est. completion 2026-12-31 1 site
    Other conditions: Kidney Tansplant, Acute Rejection (AR) of Transplanted Kidney
    View official trial listing →
  • Recruiting NCT NCT07085728

    Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

    Not yet reported Eastern Cooperative Oncology Group 74 participants Est. completion 2038-09-11 1 site Stand-alone
    Other conditions: Myeloma Multiple
    View official trial listing →
  • Recruiting NCT NCT07087314

    A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence

    Not yet reported Mao Jianhua 30 participants Est. completion 2029-07-09 1 site
    Other conditions: Nephrotic Syndrome in Children
    View official trial listing →
  • Recruiting NCT NCT07095452

    A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Not yet reported, Not yet reported AbbVie 680 participants Est. completion 2041-05 49 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07107529

    Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

    Not yet reported European Myeloma Network B.V. 150 participants Est. completion 2034-02 29 sites Stand-alone
    Other conditions: Multiple Myeloma (MM)
    View official trial listing →
  • Recruiting NCT NCT07110844

    Teclistamab-Daratumumab in AL Amyloidosis

    Not yet reported Rajshekhar Chakraborty, MD 25 participants Est. completion 2033-10 3 sites Stand-alone
    Other conditions: Amyloid Light-chain Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT07149857

    A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

    Not yet reported Janssen Research & Development, LLC 60 participants Est. completion 2029-04-06 17 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07222761

    A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

    Not yet reported Regeneron Pharmaceuticals 915 participants Est. completion 2034-08-23 24 sites Stand-alone
    Other conditions: Relapsed and/or Refractory Multiple Myeloma (RRMM)
    View official trial listing →
  • Recruiting NCT NCT07234019

    Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 160 participants Est. completion 2028-11 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia, Treatment
    View official trial listing →
  • Recruiting NCT NCT07285239

    Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

    Not yet reported PrECOG, LLC. 500 participants Est. completion 2034-06 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07297563

    Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 160 participants Est. completion 2027-11 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia, Treatment
    View official trial listing →
  • Recruiting NCT NCT07335887

    Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis

    Not yet reported Peking University People's Hospital 39 participants Est. completion 2028-08-31 3 sites Stand-alone
    Other conditions: AL Amyloidosis (AL), t(11;14) Positive
    View official trial listing →
  • Recruiting NCT NCT07341867

    Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

    Not yet reported Andrew Hantel, MD 90 participants Est. completion 2029-03-31 1 site Stand-alone
    Other conditions: Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation, Duffy Blood Group, Chemokine Receptor Gene C.-67T>C
    View official trial listing →
  • Recruiting NCT NCT07362199

    Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 20 participants Est. completion 2027-03 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia, Treatment
    View official trial listing →
  • Recruiting NCT NCT07362238

    Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 122 participants Est. completion 2028-03 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia, Treatment
    View official trial listing →
  • Recruiting NCT NCT07391657

    A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

    Not yet reported AstraZeneca 508 participants Est. completion 2030-07-29 143 sites
    Other conditions: Relapsed Refractory Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07393282

    A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

    Not yet reported Regeneron Pharmaceuticals 270 participants Est. completion 2033-07-27 14 sites
    Other conditions: High Risk Smoldering Multiple Myeloma (HR-SMM)
    View official trial listing →
  • Recruiting NCT NCT07452198

    A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported Genrix (Shanghai) Biopharmaceutical Co., Ltd. 358 participants Est. completion 2030-03 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07477587

    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported Shanghai Henlius Biotech 258 participants Est. completion 2028-02-22 81 sites
    Other conditions: Multiple Myeloma (MM)
    View official trial listing →
  • Recruiting NCT NCT07485647

    Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing

    Not yet reported Eden Biltibo 50 participants Est. completion 2029-04 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07513129

    Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

    Not yet reported M.D. Anderson Cancer Center 18 participants Est. completion 2031-12-31 1 site Stand-alone
    Other conditions: T-cell Acute Lymphoblastic Leukemia, Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07513948

    Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura

    Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico 40 participants Est. completion 2026-08 1 site
    Other conditions: Thrombotic Thrombocytopenic Purpura, Acquired
    View official trial listing →
  • Recruiting NCT NCT07555938

    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

    Not yet reported Hoffmann-La Roche 380 participants Est. completion 2033-01-31 75 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07605416

    Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

    Not yet reported National Cancer Institute (NCI) 74 participants Est. completion 2032-11-06 2 sites Stand-alone
    Other conditions: Plasma Cell Leukemia
    View official trial listing →
  • Recruiting NCT NCT07623798

    A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

    Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 255 participants Est. completion 2029-12-31 1 site
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07638683

    A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).

    Not yet reported Shanghai Zhongshan Hospital 30 participants Est. completion 2028-12-30 1 site Stand-alone
    Other conditions: Multiple Myeloma, AL Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT07649525

    Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level

    Not yet reported University of Leeds 1226 participants Est. completion 2037-06 5 sites Stand-alone
    Other conditions: Multiple Myeloma (MM), Plasma Cell Leukemia (PCL)
    View official trial listing →
  • Recruiting NCT NCT07681596

    A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported AstraZeneca 101 participants Est. completion 2031-03-06 12 sites Stand-alone
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07714512

    Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia

    Not yet reported, Not yet reported Institute of Hematology & Blood Diseases Hospital, China 32 participants Est. completion 2028-12-31 1 site
    Other conditions: Aplastic Anemia
    View official trial listing →
  • Recruiting NCT NCT07742215

    A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)

    Not yet reported Biocad 390 participants Est. completion 2032-10 16 sites Stand-alone
    Other conditions: Myeloma Multiple
    View official trial listing →
  • Recruiting NCT NCT07764978

    Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

    Not yet reported AstraZeneca 750 participants Est. completion 2034-05-12 124 sites Stand-alone
    Other conditions: Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07772024

    Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma

    Not yet reported CellCentric Ltd. 450 participants Est. completion 2031-11 1 site
    Other conditions: Multiple Myeloma Refractory, Multiple Myeloma in Relapse
    View official trial listing →
  • Recruiting NCT NCT07788456

    Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 38 participants Est. completion 2027-06-30 1 site Stand-alone
    Other conditions: ITP - Immune Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT00574288

    Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 104 participants Est. completion 2017-04-03 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01084252

    Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

    Not yet reported, Not yet reported Sanofi 351 participants Est. completion 2023-07-13 59 sites
    Other conditions: Hematological Malignancy
    View official trial listing →
  • Completed NCT NCT01415882

    Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

    Not yet reported Mayo Clinic 165 participants Est. completion 2025-04-30 3 sites Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT01592370

    An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

    Not yet reported, Not yet reported Bristol-Myers Squibb 320 participants Est. completion 2024-07-09 43 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01615029

    Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

    Not yet reported, Not yet reported Janssen Research & Development, LLC 45 participants Est. completion 2024-10-23 8 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01665794

    Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported University of Chicago 25 participants Est. completion 2025-11-14 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01749969

    SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients

    Not yet reported Sanofi 57 participants Est. completion 2023-06-20 5 sites
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT01946477

    Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

    Not yet reported Celgene 186 participants Est. completion 2025-05-26 49 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01985126

    An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

    Not yet reported Janssen Research & Development, LLC 124 participants Est. completion 2017-05-30 23 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01998971

    A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 240 participants Est. completion 2024-01-11 22 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02060188

    A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

    Not yet reported Bristol-Myers Squibb 385 participants Est. completion 2024-10-22 32 sites Stand-alone
    Obstructive sleep apnea Other conditions: Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer
    View official trial listing →
  • Completed NCT NCT02076009

    A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 569 participants Est. completion 2024-11-21 145 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02116569

    A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Pharmaceutical K.K. 9 participants Est. completion 2015-09 2 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02136134

    Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 498 participants Est. completion 2024-01-10 105 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02195479

    A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 706 participants Est. completion 2024-08-07 160 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02252172

    Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 737 participants Est. completion 2024-10-02 206 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02283775

    SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients

    Not yet reported Sanofi 54 participants Est. completion 2021-05-26 13 sites
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT02316106

    A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 123 participants Est. completion 2024-06-03 57 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02336815

    Selinexor Treatment of Refractory Myeloma

    Not yet reported Karyopharm Therapeutics Inc 202 participants Est. completion 2019-07-26 61 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT02413489

    An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

    Not yet reported Janssen Research & Development, LLC 36 participants Est. completion 2017-06-01 35 sites Stand-alone
    Other conditions: Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
    View official trial listing →
  • Completed NCT NCT02419118

    "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "

    Not yet reported, Not yet reported Vejle Hospital 4 participants Est. completion 2015-10-01 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02431208

    A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

    Not yet reported Hoffmann-La Roche 85 participants Est. completion 2021-03-19 31 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Approved For Marketing NCT NCT02477891

    Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma

    Janssen Research & Development, LLC 79 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02488759

    An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors

    Not yet reported, Not yet reported Bristol-Myers Squibb 578 participants Est. completion 2022-10-24 40 sites Stand-alone
    Other conditions: Various Advanced Cancer
    View official trial listing →
  • Completed NCT NCT02497378

    A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Pharmaceutical K.K. 8 participants Est. completion 2018-03-06 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02513186

    Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

    Not yet reported Sanofi 90 participants Est. completion 2024-01-22 12 sites
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT02514668

    A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma

    Not yet reported Sanofi 55 participants Est. completion 2021-12-02 18 sites
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT02519452

    A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 120 participants Est. completion 2023-04-03 12 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02541383

    A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma

    Not yet reported Intergroupe Francophone du Myelome 1085 participants Est. completion 2023-09-01 107 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02626481

    Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma

    Not yet reported University Hospital, Lille 64 participants Est. completion 2020-03-09 41 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02751255

    Daratumumab in Combination With ATRA

    Not yet reported, Not yet reported Amsterdam UMC, location VUmc 60 participants Est. completion 2022-10-18 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT02773030

    A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

    Not yet reported, Not yet reported Celgene 466 participants Est. completion 2028-07-28 162 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT02807454

    A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma

    Not yet reported Celgene 37 participants Est. completion 2022-01-03 64 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02807558

    A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

    Not yet reported Syros Pharmaceuticals 155 participants Est. completion 2023-01-25 26 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Completed NCT NCT02812706

    Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients

    Not yet reported, Not yet reported Sanofi 36 participants Est. completion 2022-09-28 13 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02816476

    Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis

    Not yet reported University Hospital, Limoges 40 participants Est. completion 2020-10 10 sites Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Completed NCT NCT02841033

    Daratumumab for the Treatment of Patients With AL Amyloidosis

    Not yet reported, Not yet reported Boston Medical Center 22 participants Est. completion 2020-07-17 1 site Stand-alone
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Completed NCT NCT02852837

    Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy

    Not yet reported Janssen Research & Development, LLC 50 participants Est. completion 2019-12-13 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02874742

    Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 224 participants Est. completion 2022-04-08 36 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02918331

    A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation

    Not yet reported Janssen Pharmaceutical K.K. 7 participants Est. completion 2020-03 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02927925

    A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type

    Not yet reported Janssen Research & Development, LLC 32 participants Est. completion 2020-01-07 17 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT02944565

    Daratumumab in Treating Patients With Multiple Myeloma

    Not yet reported Ohio State University Comprehensive Cancer Center 28 participants Est. completion 2017-07-20 1 site Stand-alone
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT02951819

    A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma

    Not yet reported Janssen Scientific Affairs, LLC 101 participants Est. completion 2020-08-17 26 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT02955810

    Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)

    Not yet reported National University of Ireland, Galway, Ireland 18 participants Est. completion 2020-11 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02963493

    A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported Oncopeptides AB 157 participants Est. completion 2021-11-16 20 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02970747

    Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients

    iOMEDICO AG 359 participants Est. completion 2025-04-26 1 site
    Other conditions: Multiple Myeloma in Relapse
    View official trial listing →
  • Completed NCT NCT02977494

    Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment

    Not yet reported Universitätsklinikum Hamburg-Eppendorf 22 participants Est. completion 2021-06 10 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02990338

    Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients

    Not yet reported Sanofi 307 participants Est. completion 2023-11-01 111 sites
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT02999633

    Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia

    Not yet reported Sanofi 14 participants Est. completion 2017-11-14 17 sites
    Other conditions: T-cell Type Acute Leukemia-Precursor, T-lymphoblastic Lymphoma/Leukaemia
    View official trial listing →
  • Completed NCT NCT03000452

    A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

    Not yet reported Celgene 18 participants Est. completion 2017-12-04 25 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03004287

    2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

    Not yet reported University of Arkansas 50 participants Est. completion 2028-10 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03011034

    Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

    Not yet reported Janssen Research & Development, LLC 34 participants Est. completion 2021-10-05 21 sites Stand-alone
    Other conditions: Myelodysplastic Syndromes
    View official trial listing →
  • Completed NCT NCT03012880

    Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported Mayo Clinic 80 participants Est. completion 2022-12-15 1 site Stand-alone
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT03023423

    A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

    Not yet reported, Not yet reported Janssen Research & Development, LLC 100 participants Est. completion 2019-09-26 47 sites Stand-alone
    Other conditions: Carcinoma, Non-Small-Cell Lung
    View official trial listing →
  • Withdrawn NCT NCT03035357

    Neoadjuvant Listeria or Daratumumab in Prostate Cancer

    Not yet reported M.D. Anderson Cancer Center Est. completion 2019-03-01 Stand-alone
    Other conditions: Malignant Neoplasms of Male Genital Organs, Prostate Cancer
    View official trial listing →
  • Terminated NCT NCT03067571

    Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

    Not yet reported M.D. Anderson Cancer Center 7 participants Est. completion 2022-11-21 1 site Stand-alone
    Other conditions: High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT03068351

    Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma

    Not yet reported Hoffmann-La Roche 24 participants Est. completion 2019-08-01 12 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03095118

    Daratumumab in Treatment of PGNMID and C3 GN

    Not yet reported Fernando Fervenza 12 participants Est. completion 2020-05-12 1 site Stand-alone
    Other conditions: Membranoproliferative Glomerulonephritis
    View official trial listing →
  • Completed NCT NCT03098550

    A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

    Not yet reported, Not yet reported Bristol-Myers Squibb 105 participants Est. completion 2020-07-06 20 sites Stand-alone
    Other conditions: Advanced Cancer
    View official trial listing →
  • Status unknown NCT NCT03143036

    Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma

    Not yet reported National University Hospital, Singapore 100 participants Est. completion 2022-07-01 5 sites Stand-alone
    Other conditions: Relapse and / or Refractory Myeloma
    View official trial listing →
  • Completed NCT NCT03158688

    Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

    Not yet reported Amgen 466 participants Est. completion 2022-04-15 113 sites Stand-alone
    Other conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03177460

    Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer

    Not yet reported M.D. Anderson Cancer Center 33 participants Est. completion 2024-01-30 1 site Stand-alone
    Other conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Testosterone Greater Than 150 ng/dL
    View official trial listing →
  • Completed NCT NCT03180736

    Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex

    Not yet reported Stichting European Myeloma Network 304 participants Est. completion 2024-11-30 40 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03184194

    Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide

    Not yet reported Amsterdam UMC, location VUmc 62 participants Est. completion 2024-01-25 9 sites Stand-alone
    Other conditions: Myeloma
    View official trial listing →
  • Completed NCT NCT03187262

    A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia

    Not yet reported Dana-Farber Cancer Institute 13 participants Est. completion 2021-12-31 5 sites Stand-alone
    Other conditions: Waldenström Macroglobulinemia
    View official trial listing →
  • Status unknown NCT NCT03188172

    MUK Nine b: OPTIMUM Treatment Protocol

    Not yet reported University of Leeds 95 participants Est. completion 2026-05-31 21 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03194867

    Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

    Not yet reported, Not yet reported Sanofi 109 participants Est. completion 2023-04-05 30 sites
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT03201965

    A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

    Not yet reported Janssen Research & Development, LLC 416 participants Est. completion 2024-11-19 140 sites Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Withdrawn NCT NCT03207542

    Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)

    Not yet reported M.D. Anderson Cancer Center Est. completion 2021-07 Stand-alone
    Other conditions: Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
    View official trial listing →
  • Completed NCT NCT03215524

    A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide

    Not yet reported Canadian Myeloma Research Group 120 participants Est. completion 2022-06-24 11 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03217812

    A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

    Not yet reported Janssen Research & Development, LLC 220 participants Est. completion 2024-03-08 44 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT03221634

    Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

    Not yet reported Merck Sharp & Dohme LLC Est. completion 2021-06-10 23 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03224507

    Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma

    Not yet reported University of Alabama at Birmingham 123 participants Est. completion 2023-06-30 4 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03234972

    A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 213 participants Est. completion 2024-02-27 27 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03236428

    Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

    Not yet reported Dana-Farber Cancer Institute 42 participants Est. completion 2026-10-04 6 sites Stand-alone
    Other conditions: Monoclonal Gammopathy, Smoldering Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03242889

    A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Pharmaceutical K.K. 6 participants Est. completion 2023-02-10 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03275285

    Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

    Not yet reported Sanofi 302 participants Est. completion 2025-01-03 70 sites
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT03277105

    A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 522 participants Est. completion 2024-01-12 146 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03283917

    Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

    Not yet reported M.D. Anderson Cancer Center 21 participants Est. completion 2026-06-17 1 site Stand-alone
    Other conditions: Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
    View official trial listing →
  • Active, not recruiting NCT NCT03289299

    Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

    Not yet reported International Myeloma Foundation 87 participants Est. completion 2031-11-15 10 sites Stand-alone
    Other conditions: Smoldering Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03290950

    A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported Memorial Sloan Kettering Cancer Center 69 participants Est. completion 2026-09 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03301220

    A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 390 participants Est. completion 2026-05-04 163 sites Stand-alone
    Other conditions: Smoldering Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03311828

    Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma

    Not yet reported City of Hope Medical Center 12 participants Est. completion 2023-06-05 1 site Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Plasma Cell Myeloma, Secondary Amyloidosis
    View official trial listing →
  • Active, not recruiting NCT NCT03314181

    A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported AbbVie 156 participants Est. completion 2031-05 40 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03319667

    A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Not yet reported Sanofi 475 participants Est. completion 2027-06-30 104 sites
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT03320707

    A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants

    Not yet reported Janssen Research & Development, LLC 66 participants Est. completion 2019-08-27 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Active, not recruiting NCT NCT03346135

    Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma

    Not yet reported City of Hope Medical Center 31 participants Est. completion 2027-05-17 2 sites Stand-alone
    Other conditions: Plasma Cell Myeloma, Secondary Amyloidosis
    View official trial listing →
  • Completed NCT NCT03357952

    A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported Janssen Research & Development, LLC 10 participants Est. completion 2021-11-19 13 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT03367819

    Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

    Not yet reported, Not yet reported Sanofi 44 participants Est. completion 2021-03-10 16 sites
    Other conditions: Prostate Cancer, Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT03384654

    A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    Not yet reported Janssen Research & Development, LLC 47 participants Est. completion 2022-09-27 53 sites Stand-alone
    Other conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma
    View official trial listing →
  • Completed NCT NCT03412565

    A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

    Not yet reported Janssen Research & Development, LLC 265 participants Est. completion 2024-04-18 64 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT03432741

    Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

    Not yet reported Mayo Clinic 17 participants Est. completion 2022-10-03 1 site Stand-alone
    Other conditions: Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
    View official trial listing →
  • Completed NCT NCT03439293

    A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

    Not yet reported Takeda 61 participants Est. completion 2023-06-26 28 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03447808

    Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

    Not yet reported Jennifer Woyach 15 participants Est. completion 2026-05-26 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT03450057

    Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment

    Not yet reported Hellenic Society of Hematology 38 participants Est. completion 2021-03-22 1 site Stand-alone
    Other conditions: Relapsed/Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03473730

    Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

    Not yet reported M.D. Anderson Cancer Center 17 participants Est. completion 2025-01-27 1 site Stand-alone
    Other conditions: Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Neoplasm, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC V8
    View official trial listing →
  • Status unknown NCT NCT03475628

    Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma

    Not yet reported Hellenic Society of Hematology 57 participants Est. completion 2020-02-20 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03477539

    Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

    Not yet reported Mayo Clinic 49 participants Est. completion 2025-03-24 1 site Stand-alone
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT03481556

    Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM

    Not yet reported, Not yet reported Oncopeptides AB 56 participants Est. completion 2022-02-02 16 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03490344

    Short Course Daratumumab in Patients With Multiple Myeloma

    Not yet reported Memorial Sloan Kettering Cancer Center 10 participants Est. completion 2023-03-23 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03500445

    Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

    Not yet reported University of Chicago 75 participants Est. completion 2026-06 1 site Stand-alone
    Other conditions: Myeloma, Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT03537599

    Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

    Not yet reported, Not yet reported Sumithira Vasu 4 participants Est. completion 2022-02-03 1 site Stand-alone
    Other conditions: Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03556332

    A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

    Not yet reported Memorial Sloan Kettering Cancer Center 41 participants Est. completion 2027-07 12 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03589222

    SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

    Not yet reported PETHEMA Foundation 62 participants Est. completion 2026-08 15 sites Stand-alone
    Other conditions: Refractory Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT03590652

    Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

    Not yet reported University of California, San Diego 23 participants Est. completion 2025-07-02 4 sites Stand-alone
    Other conditions: Relapsed/Refractory Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT03591744

    Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

    Not yet reported City of Hope Medical Center Est. completion 2019-10-25 5 sites Stand-alone
    Other conditions: Plasma Cell Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03606577

    An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients

    Not yet reported Nantes University Hospital 50 participants Est. completion 2027-11-08 12 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03619252

    Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents

    Not yet reported Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology 36 participants Est. completion 2021-06-30 1 site Stand-alone
    Other conditions: Multiple Myeloma, Pneumococcal Infection, Febrile Neutropenia, Pneumococcal Pneumonia
    View official trial listing →
  • Terminated NCT NCT03622775

    Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant

    Not yet reported M.D. Anderson Cancer Center 13 participants Est. completion 2025-10-09 1 site Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT03637764

    Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

    Not yet reported, Not yet reported Sanofi 107 participants Est. completion 2022-05-11 26 sites
    Other conditions: Neoplasm
    View official trial listing →
  • Completed NCT NCT03651128

    Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

    Not yet reported Celgene 386 participants Est. completion 2026-04-13 62 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03652064

    A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

    Not yet reported Janssen Research & Development, LLC 395 participants Est. completion 2026-04-21 114 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03665155

    First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody

    Not yet reported, Not yet reported Memorial Sloan Kettering Cancer Center 11 participants Est. completion 2020-04-20 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT03669445

    Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma

    Not yet reported University Hospital, Toulouse 45 participants Est. completion 2024-12 12 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT03679624

    Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

    Not yet reported Weill Medical College of Cornell University 1 participants Est. completion 2020-10-13 1 site Stand-alone
    Other conditions: Waldenstrom Macroglobulinemia, Waldenstrom's Disease, Waldenström; Hypergammaglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia of Lymph Nodes, Waldenstrom's Macroglobulinaemia, Without Mention of Remission, Waldenstrom's Macroglobulinemia Refractory
    View official trial listing →
  • Status unknown NCT NCT03695744

    Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma

    Not yet reported Singapore General Hospital 27 participants Est. completion 2024-04 2 sites Stand-alone
    Other conditions: Multiple Myeloma, Myeloma
    View official trial listing →
  • Completed NCT NCT03697629

    A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma

    Not yet reported Canadian Myeloma Research Group 40 participants Est. completion 2021-12-20 6 sites Stand-alone
    Other conditions: Multiple Myeloma in Relapse
    View official trial listing →
  • Status unknown NCT NCT03697655

    Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma

    Not yet reported Polish Myeloma Consortium 274 participants Est. completion 2024-07 2 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT03701321

    Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported National Cancer Institute (NCI) Est. completion 2020-05-28 3 sites Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03710603

    Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

    Not yet reported Stichting European Myeloma Network 709 participants Est. completion 2029-11 13 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03732703

    Myeloma-Developing Regimens Using Genomics (MyDRUG)

    Not yet reported, Not yet reported Multiple Myeloma Research Consortium 103 participants Est. completion 2024-12-31 16 sites Stand-alone
    Other conditions: Relapsed Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03733717

    Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma

    Not yet reported Sanofi 25 participants Est. completion 2023-08-25 3 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03734198

    Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

    Not yet reported French Innovative Leukemia Organisation 29 participants Est. completion 2025-12-19 24 sites Stand-alone
    Other conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03742297

    Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

    Not yet reported PETHEMA Foundation 462 participants Est. completion 2031-01 58 sites Stand-alone
    Other conditions: Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT03746652

    Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported Hellenic Society of Hematology 50 participants Est. completion 2021-12 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT03757221

    Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma

    Not yet reported University Hospital, Caen 55 participants Est. completion 2024-04-28 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03763162

    Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported M.D. Anderson Cancer Center 40 participants Est. completion 2027-10-30 1 site Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT03768960

    A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent

    Not yet reported Johnson & Johnson Private Limited 150 participants Est. completion 2022-07-16 16 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT03769181

    A Study of Isatuximab-based Therapy in Participants With Lymphoma

    Not yet reported, Not yet reported Sanofi 58 participants Est. completion 2022-11-08 20 sites
    Other conditions: Lymphoma
    View official trial listing →
  • Status unknown NCT NCT03792620

    Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation

    Not yet reported Grupo de Estudos Multicentricos em Onco-Hematologia 20 participants Est. completion 2022-04 1 site Stand-alone
    Other conditions: Multiple Myeloma Stage I
    View official trial listing →
  • Active, not recruiting NCT NCT03829371

    STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

    Not yet reported University of Turin, Italy 450 participants Est. completion 2030-01-03 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03836014

    Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

    Not yet reported Assistance Publique - Hôpitaux de Paris 436 participants Est. completion 2026-07 1 site Stand-alone
    Other conditions: Multiple Myeloma in Relapse
    View official trial listing →
  • Terminated NCT NCT03837509

    INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported Incyte Corporation 15 participants Est. completion 2022-04-05 29 sites Stand-alone
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT03841565

    Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

    Not yet reported Academic and Community Cancer Research United Est. completion 2022-02-09 5 sites Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT03860844

    Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

    Not yet reported Sanofi 67 participants Est. completion 2023-05-26 41 sites
    Other conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT03871829

    Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

    Not yet reported Janssen Research & Development, LLC 88 participants Est. completion 2023-01-10 108 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03896737

    Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

    Not yet reported European Myeloma Network B.V. 401 participants Est. completion 2027-09-15 24 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03901963

    A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

    Not yet reported Janssen Research & Development, LLC 200 participants Est. completion 2026-05-04 73 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT03942224

    Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported Emory University 49 participants Est. completion 2026-07-31 1 site Stand-alone
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03989414

    A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

    Not yet reported, Not yet reported Celgene 424 participants Est. completion 2026-11-30 49 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT03992170

    Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive

    Not yet reported Azienda Ospedaliera Universitaria Senese 50 participants Est. completion 2022-12-31 1 site Stand-alone
    Other conditions: Myeloma Multiple
    View official trial listing →
  • Completed NCT NCT03993912

    Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

    Not yet reported University Hospital, Lille 294 participants Est. completion 2026-08-28 23 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04009109

    Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

    Not yet reported Alliance Foundation Trials, LLC. 79 participants Est. completion 2027-06 7 sites Stand-alone
    Other conditions: Myeloma, Multiple
    View official trial listing →
  • Withdrawn NCT NCT04024384

    Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial

    Not yet reported Assistance Publique - Hôpitaux de Paris Est. completion 2024-07 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04045028

    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    Not yet reported Genentech, Inc. 41 participants Est. completion 2023-03-28 14 sites Stand-alone
    Other conditions: Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT04045795

    Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

    Not yet reported Sanofi 56 participants Est. completion 2024-03-27 14 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04052880

    Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

    Not yet reported Larysa Sanchez 17 participants Est. completion 2026-05 1 site Stand-alone
    Other conditions: Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT04065308

    Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma

    Not yet reported Seoul National University Hospital 33 participants Est. completion 2021-09-30 1 site Stand-alone
    Other conditions: Multiple Myeloma in Relapse, Plasmacytoma, Daratumumab
    View official trial listing →
  • Completed NCT NCT04065789

    Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients

    Not yet reported Tel-Aviv Sourasky Medical Center 41 participants Est. completion 2021-11-12 14 sites Stand-alone
    Other conditions: Myeloma Multiple, Myeloma, Plasma-Cell, Myeloma-Multiple, Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT04070378

    Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease

    Not yet reported Marc L Gordon, MD 16 participants Est. completion 2023-08-15 1 site Stand-alone
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Active, not recruiting NCT NCT04071457

    S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

    Not yet reported SWOG Cancer Research Network 1100 participants Est. completion 2040-07-01 842 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT04088903

    Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation

    Not yet reported Ronald Witteles Est. completion 2023-04-01 Stand-alone
    Other conditions: Allosensitization, Heart Transplant Failure and Rejection
    View official trial listing →
  • Active, not recruiting NCT NCT04108195

    A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 290 participants Est. completion 2027-04-07 24 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04113018

    Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

    Not yet reported Wake Forest University Health Sciences 39 participants Est. completion 2027-10 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT04121260

    A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 21 participants Est. completion 2023-10-13 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04124497

    A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients

    Not yet reported Fondazione EMN Italy Onlus 45 participants Est. completion 2027-07-01 15 sites Stand-alone
    Other conditions: Multiple Myeloma, Deletion 17P Syndrome
    View official trial listing →
  • Completed NCT NCT04131309

    A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

    Not yet reported Stichting European Myeloma Network 40 participants Est. completion 2025-01-27 5 sites Stand-alone
    Other conditions: Light Chain (AL) Amyloidosis, Stage 3B
    View official trial listing →
  • Active, not recruiting NCT NCT04133636

    A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 208 participants Est. completion 2028-08-25 47 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT04136756

    NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

    Not yet reported Nektar Therapeutics 30 participants Est. completion 2023-04-24 13 sites Stand-alone
    Other conditions: Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT04140162

    Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

    Not yet reported University of Michigan Rogel Cancer Center 57 participants Est. completion 2026-09-02 4 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT04150692

    Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma

    Not yet reported Washington University School of Medicine Est. completion 2026-03-31 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT04151667

    Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 33 participants Est. completion 2026-03-16 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04166565

    Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease

    Not yet reported Stichting European Myeloma Network 41 participants Est. completion 2027-03 8 sites Stand-alone
    Other conditions: Multiple Myeloma, Extramedullary Plasmacytoma
    View official trial listing →
  • Active, not recruiting NCT NCT04176718

    Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

    Not yet reported Andrew Yee, MD 44 participants Est. completion 2028-05 3 sites Stand-alone
    Other conditions: Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Relapse
    View official trial listing →
  • Active, not recruiting NCT NCT04181827

    A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 419 participants Est. completion 2027-03-31 88 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT04204980

    Desensitization in Kidney Allograft Using Daratumumab

    Not yet reported, Not yet reported Assistance Publique - Hôpitaux de Paris 21 participants Est. completion 2023-06-01 1 site Stand-alone
    Other conditions: Allosensitization, Kidney Transplant Rejection, Antibody-mediated Rejection
    View official trial listing →
  • Terminated NCT NCT04205240

    Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma

    Not yet reported Srinivas Devarakonda 1 participants Est. completion 2021-11-22 1 site Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma
    View official trial listing →
  • Enrolling by invitation NCT NCT04210791

    Autologous Stem Cell Transplantation for Patients With AL Amyloidosis

    Nanjing University School of Medicine 500 participants Est. completion 2030-12-31 1 site
    Other conditions: AL Amyloidosis, Plasma Cell Dyscrasia
    View official trial listing →
  • Withdrawn NCT NCT04223661

    Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy

    Not yet reported Attaya Suvannasankha Est. completion 2023-12-31 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT04230031

    Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma

    Not yet reported Wake Forest University Health Sciences Est. completion 2027-01 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04230304

    Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

    Not yet reported Mayo Clinic 8 participants Est. completion 2025-02-13 1 site Stand-alone
    Other conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT04246047

    Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

    Not yet reported GlaxoSmithKline 494 participants Est. completion 2028-06-30 69 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04251065

    Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

    Not yet reported Fondazione Italiana Linfomi - ETS 8 participants Est. completion 2022-11-23 7 sites Stand-alone
    Other conditions: Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma
    View official trial listing →
  • Approved For Marketing NCT NCT04264884

    Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab

    Janssen Research & Development, LLC
    View official trial listing →
  • Active, not recruiting NCT NCT04268498

    A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

    Not yet reported University of Miami 310 participants Est. completion 2027-02-01 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04270175

    Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

    Not yet reported Weill Medical College of Cornell University 15 participants Est. completion 2028-01 4 sites Stand-alone
    Other conditions: Amyloid, AL Amyloidosis, Refractory AL Amyloidosis
    View official trial listing →
  • Active, not recruiting NCT NCT04270409

    Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

    Not yet reported Sanofi 337 participants Est. completion 2033-10-21 105 sites
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT04280328

    Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported Corvus Pharmaceuticals, Inc. 7 participants Est. completion 2022-03-01 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT04288765

    Carfilzomib, Daratumumab, Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma

    Not yet reported Grupo Cooperativo de Hemopatías Malignas Est. completion 2025-02-28 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04294459

    Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation

    Not yet reported, Not yet reported Sanofi 23 participants Est. completion 2022-05-02 6 sites
    Other conditions: Immune System Disorder
    View official trial listing →
  • Active, not recruiting NCT NCT04302324

    A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

    Not yet reported Weill Medical College of Cornell University 11 participants Est. completion 2027-12-28 1 site Stand-alone
    Other conditions: Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT04304144

    A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis

    Not yet reported Alexion Pharmaceuticals, Inc. 25 participants Est. completion 2023-11-14 3 sites Stand-alone
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Status unknown NCT NCT04309981

    Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.

    Not yet reported, Not yet reported Sara V. Latorre 73 participants Est. completion 2025-04-01 7 sites
    Other conditions: Relapsed/Refractory Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04352205

    Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

    Not yet reported Emory University 17 participants Est. completion 2024-01-19 1 site Stand-alone
    Other conditions: Plasma Cell Myeloma, Renal Failure
    View official trial listing →
  • Withdrawn NCT NCT04361851

    Study of Dara-Pembro for Multiple Myeloma Patients

    Not yet reported Wake Forest University Health Sciences Est. completion 2027-05 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT04396496

    Treatment of POEMS Syndrome With Daratumumab

    Not yet reported University of Arkansas 2 participants Est. completion 2023-10-16 1 site Stand-alone
    Other conditions: POEMS Syndrome
    View official trial listing →
  • Terminated NCT NCT04407442

    Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab

    Not yet reported University of California, San Francisco 5 participants Est. completion 2023-04-30 1 site Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Withdrawn NCT NCT04466475

    Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma

    Not yet reported Fred Hutchinson Cancer Center Est. completion 2027-09-30 1 site
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Withdrawn NCT NCT04467281

    A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma

    Not yet reported Memorial Sloan Kettering Cancer Center Est. completion 2021-02-26 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT04474938

    Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis

    Not yet reported Peking Union Medical College Hospital 40 participants Est. completion 2024-03 1 site Stand-alone
    Other conditions: Amyloidosis; Systemic
    View official trial listing →
  • Active, not recruiting NCT NCT04497961

    A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide

    Not yet reported Memorial Sloan Kettering Cancer Center 95 participants Est. completion 2027-08 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT04579523

    ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

    Not yet reported Fred Hutchinson Cancer Center Est. completion 2029-12-31 1 site
    Other conditions: Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT04610320

    Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation

    Not yet reported Ronald Witteles 8 participants Est. completion 2024-01-26 1 site Stand-alone
    Other conditions: Allosensitization, Heart Transplant Failure and Rejection
    View official trial listing →
  • Terminated NCT NCT04614636

    FT538 in Subjects With Advanced Hematologic Malignancies

    Not yet reported Fate Therapeutics 42 participants Est. completion 2023-08-08 8 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma, Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04635189

    Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma

    Not yet reported University of Rochester 28 participants Est. completion 2027-09-08 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04649060

    Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma

    Not yet reported Oncopeptides AB 54 participants Est. completion 2022-02-07 26 sites Stand-alone
    Other conditions: Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04656951

    Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse

    Not yet reported University of Cologne 67 participants Est. completion 2031-12 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04667663

    CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.

    Not yet reported Cancer Trials Ireland 16 participants Est. completion 2026-04-30 3 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04700176

    A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma

    Not yet reported Hackensack Meridian Health 1 participants Est. completion 2023-11-15 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT04703621

    The DART Study- Daratumumab Treatment in ITP

    Not yet reported Ostfold Hospital Trust 21 participants Est. completion 2024-12 6 sites Stand-alone
    Other conditions: ITP
    View official trial listing →
  • Completed NCT NCT04714372

    FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia

    Not yet reported Masonic Cancer Center, University of Minnesota 9 participants Est. completion 2024-10-15 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Myeloid Leukemia, Monocytic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04722146

    A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 140 participants Est. completion 2027-10-13 27 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04756401

    Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

    Not yet reported Academic and Community Cancer Research United 8 participants Est. completion 2027-12-30 4 sites Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04775550

    DARA RVD For High Risk SMM

    Not yet reported Omar Nadeem, MD 61 participants Est. completion 2030-12-08 6 sites Stand-alone
    Other conditions: High-risk Smoldering Multiple Myeloma, Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04776018

    A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

    Not yet reported, Not yet reported Takeda 27 participants Est. completion 2023-11-09 13 sites Stand-alone
    Other conditions: Relapsed and/or Refractory Multiple Myeloma (RRMM)
    View official trial listing →
  • Active, not recruiting NCT NCT04782687

    Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

    Not yet reported US Oncology Research 73 participants Est. completion 2026-05-31 10 sites Stand-alone
    Other conditions: Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell, Myeloma-Multiple, Myelomatosis, Plasma Cell Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04790474

    Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib

    Not yet reported Tel-Aviv Sourasky Medical Center 61 participants Est. completion 2028-01-01 7 sites Stand-alone
    Other conditions: Multiple Myeloma in Relapse, Refractory Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT04810754

    An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus

    Not yet reported Charite University, Berlin, Germany 10 participants Est. completion 2023-12-31 Stand-alone
    Other conditions: Systemic Lupus Erythematosus
    View official trial listing →
  • Status unknown NCT NCT04814615

    A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma

    Not yet reported Hoag Memorial Hospital Presbyterian 60 participants Est. completion 2026-03-15 2 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04824794

    GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

    Not yet reported, Not yet reported Genmab 130 participants Est. completion 2025-07-31 52 sites
    Other conditions: Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Completed NCT NCT04827979

    Daratumumab and Belatacept for Desensitization

    Not yet reported, Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 19 participants Est. completion 2026-04-02 1 site Stand-alone
    Other conditions: Highly Sensitized Prospective Kidney Transplant Recipients
    View official trial listing →
  • Active, not recruiting NCT NCT04868838

    Daratumumab to Treat Active Lupus Nephritis

    Not yet reported Mayo Clinic 12 participants Est. completion 2026-09 1 site Stand-alone
    Other conditions: Lupus Nephritis
    View official trial listing →
  • Terminated NCT NCT04892264

    Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

    Not yet reported Mayo Clinic 5 participants Est. completion 2024-03-18 1 site Stand-alone
    Other conditions: Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT04892446

    Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

    Not yet reported Gilead Sciences 36 participants Est. completion 2024-04-25 22 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04895410

    Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

    Not yet reported AbbVie 8 participants Est. completion 2022-06-24 32 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04895917

    Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis

    Not yet reported Fondazione IRCCS Policlinico San Matteo di Pavia 27 participants Est. completion 2025-01-15 3 sites Stand-alone
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Active, not recruiting NCT NCT04922723

    Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma

    Not yet reported, Not yet reported West Virginia University 16 participants Est. completion 2026-12 1 site Stand-alone
    Other conditions: Glioblastoma
    View official trial listing →
  • Active, not recruiting NCT NCT04925193

    Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

    Not yet reported University of Colorado, Denver 18 participants Est. completion 2026-11 1 site Stand-alone
    Other conditions: Multiple Myeloma in Relapse
    View official trial listing →
  • Active, not recruiting NCT NCT04933539

    Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

    Not yet reported National Cancer Institute (NCI) 14 participants Est. completion 2032-10-31 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT04942067

    APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported Ascentage Pharma Group Inc. 108 participants Est. completion 2024-12-01 3 sites Stand-alone
    Other conditions: Multiple Myeloma, Amyloidosis
    View official trial listing →
  • Terminated NCT NCT04956302

    Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

    Not yet reported Abdullah Khan 1 participants Est. completion 2022-06-16 1 site Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT04973137

    A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

    Not yet reported Prothena Biosciences Ltd. 208 participants Est. completion 2025-06-20 110 sites Stand-alone
    Other conditions: Light Chain (AL) Amyloidosis
    View official trial listing →
  • Active, not recruiting NCT NCT04975997

    Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

    Not yet reported Celgene 939 participants Est. completion 2032-06-25 259 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT05004259

    The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia

    Not yet reported Dartmouth-Hitchcock Medical Center 2 participants Est. completion 2024-09-21 1 site Stand-alone
    Other conditions: Hemolytic Anemia
    View official trial listing →
  • Active, not recruiting NCT NCT05050097

    A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 166 participants Est. completion 2027-04-07 31 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT05054478

    Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation

    Not yet reported Assistance Publique - Hôpitaux de Paris 29 participants Est. completion 2028-02 Stand-alone
    Other conditions: Plasma Cell Leukemia
    View official trial listing →
  • Completed NCT NCT05065970

    Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

    Not yet reported HI-Bio, A Biogen Company 54 participants Est. completion 2024-05-06 59 sites
    Other conditions: Immunoglobulin A (IgA) Nephropathy
    View official trial listing →
  • Active, not recruiting NCT NCT05083169

    A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 587 participants Est. completion 2028-09-15 176 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05088330

    A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM

    Not yet reported The First Affiliated Hospital of Soochow University 76 participants Est. completion 2024-12-31 Stand-alone
    Other conditions: Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT05139225

    A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma

    Not yet reported Memorial Sloan Kettering Cancer Center 7 participants Est. completion 2026-07-01 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT05145296

    The Safety/Efficacy Of Daratumumab With Belatacept In Highly HLA-Sensitized Patients Awaiting Kidney Transplantation

    Not yet reported University Hospital, Grenoble 5 participants Est. completion 2025-10-10 1 site
    Other conditions: Sensitisation, Highly Sensitised Dialysis Patients
    View official trial listing →
  • Completed NCT NCT05182073

    FT576 in Subjects With Multiple Myeloma

    Not yet reported Fate Therapeutics 31 participants Est. completion 2024-10-18 14 sites Stand-alone
    Other conditions: Multiple Myeloma, Myeloma
    View official trial listing →
  • Withdrawn NCT NCT05205252

    A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

    Not yet reported, Not yet reported Epizyme, Inc. Est. completion 2023-07-05 3 sites
    Other conditions: Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
    View official trial listing →
  • Status unknown NCT NCT05218603

    Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

    PETHEMA Foundation 100 participants Est. completion 2025-11-06 32 sites
    Other conditions: Multiple Myeloma, Non-eligible for Autologous Stem Cell Transplantation (ASCT)
    View official trial listing →
  • Active, not recruiting NCT NCT05231629

    Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

    Not yet reported University of Alabama at Birmingham 300 participants Est. completion 2029-12 10 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT05243342

    A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

    Not yet reported Genentech, Inc. 18 participants Est. completion 2024-07-10 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05250973

    A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

    Not yet reported Janssen Research & Development, LLC 151 participants Est. completion 2026-10-26 46 sites Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Active, not recruiting NCT NCT05257083

    A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

    Not yet reported Stichting European Myeloma Network 759 participants Est. completion 2040-08 106 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05259839

    A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

    Not yet reported AbbVie 283 participants Est. completion 2033-09 49 sites Stand-alone
    Other conditions: Relapsed/Refractory Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05277493

    A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab

    Peking Union Medical College Hospital 500 participants Est. completion 2025-09 1 site
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Status unknown NCT NCT05280275

    A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

    Not yet reported, Not yet reported Hellenic Society of Hematology 36 participants Est. completion 2026-03-15 2 sites Stand-alone
    Other conditions: Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease
    View official trial listing →
  • Completed NCT NCT05284591

    Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)

    iOMEDICO AG 96 participants Est. completion 2024-09-20 1 site
    Other conditions: Multiple Myeloma, Newly Diagnosed, Transplant Ineligible, Patient Satisfaction, Patient Preference, Personal Satisfaction
    View official trial listing →
  • Enrolling by invitation NCT NCT05300451

    Daratumumab in HLA Desensitization Prior to Transplantation

    Not yet reported Barry A. Boilson 10 participants Est. completion 2026-08 1 site Stand-alone
    Other conditions: Cardiac Transplant
    View official trial listing →
  • Completed NCT NCT05306587

    Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project.

    Thomas Lund 40 participants Est. completion 2024-01-01 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05308654

    A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

    Not yet reported AbbVie 34 participants Est. completion 2025-12 21 sites Stand-alone
    Other conditions: Relapsed/Refractory Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05392946

    Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

    Not yet reported, Not yet reported Mayo Clinic 49 participants Est. completion 2028-09-29 1 site Stand-alone
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05403138

    Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders

    Not yet reported, Not yet reported Tianjin Medical University General Hospital 135 participants Est. completion 2025-12-01 1 site Stand-alone
    Other conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder
    View official trial listing →
  • Withdrawn NCT NCT05408026

    Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM

    Not yet reported, Not yet reported Alliance Foundation Trials, LLC. Est. completion 2026-02 Stand-alone
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05434689

    COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide

    Not yet reported, Not yet reported University of Alabama at Birmingham 80 participants Est. completion 2028-08 4 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05438043

    A Study of Daratumumab

    Not yet reported Janssen Research & Development, LLC 213 participants Est. completion 2029-01-31 92 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05451771

    Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

    Not yet reported, Not yet reported Columbia University 53 participants Est. completion 2027-09 5 sites
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Active, not recruiting NCT NCT05455320

    A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

    Not yet reported Janssen Research & Development, LLC 864 participants Est. completion 2028-05-25 216 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT05486481

    Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)

    Not yet reported, Not yet reported Alfred Chung, MD Est. completion 2028-12-31 Stand-alone
    Other conditions: AL Amyloidosis, Light Chain (AL) Amyloidosis, Systemic Light Chain Disease
    View official trial listing →
  • Active, not recruiting NCT NCT05497804

    Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

    Not yet reported Mayo Clinic 17 participants Est. completion 2028-09-04 3 sites Stand-alone
    Other conditions: ISS Stage III Plasma Cell Myeloma, Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT05511428

    Home Based Daratumumab Administration for Patients With Multiple Myeloma

    Not yet reported Thomas Jefferson University 20 participants Est. completion 2024-05-22 1 site Stand-alone
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05527340

    Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

    Not yet reported PETHEMA Foundation 140 participants Est. completion 2029-12 9 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT05556616

    A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

    Not yet reported Teva Branded Pharmaceutical Products R&D LLC 15 participants Est. completion 2024-06-04 21 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05559788

    Real-World Use of Selinexor, Daratumumab and Dexamethasone in Chinese Patients With Multiple Myeloma at First Relapse

    Fu chengcheng PhD 34 participants Est. completion 2025-06-01
    Other conditions: Multiple Myeloma at First Relapse
    View official trial listing →
  • Status unknown NCT NCT05561049

    Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma

    The First Affiliated Hospital of Soochow University 120 participants Est. completion 2025-09-30
    Other conditions: Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05562882

    A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 60 participants Est. completion 2025-12-31 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Active, not recruiting NCT NCT05572515

    A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 614 participants Est. completion 2031-08-31 211 sites
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT05581875

    A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

    Not yet reported, Not yet reported Hellenic Society of Hematology 48 participants Est. completion 2026-10-31 Stand-alone
    Other conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Neoplasms, Gammopathy, Monoclonal, Paraproteinemias, Blood Protein Disorders, Haematologic Disease, Corneal Disease, Neoplasms, Plasma Cell
    View official trial listing →
  • Terminated NCT NCT05590377

    A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported Teva Branded Pharmaceutical Products R&D LLC 15 participants Est. completion 2024-05-22 27 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT05641324

    A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

    Not yet reported Anaveon AG 4 participants Est. completion 2023-07-12 11 sites Stand-alone
    Other conditions: Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma, Adult Disease, Hematologic Diseases
    View official trial listing →
  • Active, not recruiting NCT NCT05654506

    Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits

    Not yet reported Mayo Clinic 40 participants Est. completion 2028-08 4 sites Stand-alone
    Other conditions: Proliferative Glomerulonephritis With Monoclonal IgG Deposits
    View official trial listing →
  • Terminated NCT NCT05675319

    Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

    Not yet reported Universitätsklinikum Hamburg-Eppendorf 28 participants Est. completion 2025-03-21 30 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT05679258

    A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects

    Not yet reported Shanghai Henlius Biotech 172 participants Est. completion 2024-06-28 2 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05704400

    Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome

    Not yet reported Istituto Giannina Gaslini 20 participants Est. completion 2025-03-01 1 site Stand-alone
    Other conditions: Nephrotic Syndrome
    View official trial listing →
  • Status unknown NCT NCT05776940

    Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis

    Not yet reported Air Force Military Medical University, China 116 participants Est. completion 2026-03-31
    Other conditions: Immunoglobulin Light-chain Amyloidosis
    View official trial listing →
  • Completed NCT NCT05807048

    Daratumumab in STK11 Mutated NSCLC

    Not yet reported NYU Langone Health 8 participants Est. completion 2025-11-11 1 site Stand-alone
    Other conditions: Non-small Cell Lung Cancer With STK11/LKB1 Mutation
    View official trial listing →
  • Completed NCT NCT05832216

    Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 10 participants Est. completion 2024-12-01 1 site Stand-alone
    Other conditions: Aplastic Anemia, Platelet Transfusion Refractoriness
    View official trial listing →
  • Completed NCT NCT05835726

    Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.

    Fondazione Policlinico Universitario Agostino Gemelli IRCCS 188 participants Est. completion 2025-01-31 1 site
    Other conditions: Multiple Myeloma, Daratumumab, Autologous Stem Cell Transplantation, Leukapheresis
    View official trial listing →
  • Active, not recruiting NCT NCT05849610

    Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

    Not yet reported PETHEMA Foundation 30 participants Est. completion 2029-07 10 sites Stand-alone
    Other conditions: High-Risk de Novo Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05857982

    Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

    Not yet reported, Not yet reported Second Affiliated Hospital of Soochow University 20 participants Est. completion 2025-12-31 1 site Stand-alone
    Other conditions: Relapsed/Refractory Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05913596

    The Safety and Efficacy of CD38 Monoclonal Antibody Monotherapy for CaAMR in Renal Transplantation

    Not yet reported First Affiliated Hospital of Zhejiang University 15 participants Est. completion 2024-08-30 1 site Stand-alone
    Other conditions: Antibody-mediated Rejection, Kidney Tranplant
    View official trial listing →
  • Completed NCT NCT05974969

    A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subjects

    Not yet reported Biocad 146 participants Est. completion 2023-08-15 3 sites Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Active, not recruiting NCT NCT06015724

    Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

    Not yet reported Georgetown University 19 participants Est. completion 2027-06 1 site Stand-alone
    Other conditions: Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06042725

    MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

    Not yet reported Mayo Clinic 16 participants Est. completion 2027-05-29 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT06046287

    Daratumumab for Polyneuropathy Associated With MGUS

    Not yet reported Georgetown University Est. completion 2025-09-26 2 sites Stand-alone
    Other conditions: Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance
    View official trial listing →
  • Completed NCT NCT06055075

    A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported Hoffmann-La Roche 19 participants Est. completion 2025-07-08 7 sites Stand-alone
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT06169215

    Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

    Not yet reported National Cancer Institute (NCI) 70 participants Est. completion 2026-09-30 27 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT06170151

    Role of18F-FDG PET-CT for Assessing and Predicting Response to Daratumumab and for Prognosis With Multiple Myeloma

    IRCCS San Raffaele 10 participants Est. completion 2022-12-01 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT06189833

    Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS

    Not yet reported Stichting European Myeloma Network 200 participants Est. completion 2025-12 31 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT06232707

    A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

    Not yet reported Celgene Est. completion 2030-09-21 170 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT06253637

    Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program

    Not yet reported Gruppo Italiano Malattie EMatologiche dell'Adulto 31 participants Est. completion 2029-10 3 sites Stand-alone
    Other conditions: T-Lymphocytic Leukemia, Acute
    View official trial listing →
  • Status unknown NCT NCT06296121

    A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma

    Not yet reported Biocad 252 participants Est. completion 2026-07 14 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT06297681

    Combination of Daratumumab and BD Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac Disease

    Beijing Chao Yang Hospital 40 participants Est. completion 2025-12-31
    Other conditions: M-protein Related Cardiac Disease
    View official trial listing →
  • Withdrawn NCT NCT06348147

    Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

    Not yet reported UNC Lineberger Comprehensive Cancer Center Est. completion 2029-05 1 site Stand-alone
    Other conditions: Newly Diagnosed Multiple Myeloma, Multiple Myeloma, Autologous Stem Cell Transplantation
    View official trial listing →
  • Active, not recruiting NCT NCT06353022

    Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

    Not yet reported Nantes University Hospital 103 participants Est. completion 2030-06-26 19 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT06371534

    A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults

    Not yet reported Qilu Pharmaceutical Co., Ltd. 228 participants Est. completion 2025-04 2 sites
    Other conditions: Tumor
    View official trial listing →
  • Active, not recruiting NCT NCT06413498

    A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

    Not yet reported Kite, A Gilead Company 452 participants Est. completion 2031-07 117 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT06455748

    Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study

    Not yet reported Yongyong MA 20 participants Est. completion 2025-03-01 1 site Stand-alone
    Other conditions: Amyloid Light-chain Amyloidosis
    View official trial listing →
  • Completed NCT NCT06483139

    Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy

    Brigham and Women's Hospital 549 participants Est. completion 2026-06-01 1 site
    Other conditions: Multiple Myeloma, Light Chain Nephropathy, Acute Kidney Injury
    View official trial listing →
  • Completed NCT NCT06549634

    Biomarkers of AKI in Patients Receiving Daratumumab

    Brigham and Women's Hospital 20 participants Est. completion 2026-01-15 1 site
    Other conditions: Acute Kidney Injury, Multiple Myeloma, Light Chain Nephropathy
    View official trial listing →
  • Withdrawn NCT NCT06570915

    Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China Est. completion 2028-09-01 Stand-alone
    Other conditions: ALL, Adult
    View official trial listing →
  • Completed NCT NCT06571864

    AL Amyloidosis and Anti-CD38-Daratunumab

    Not yet reported University of Turin, Italy 14 participants Est. completion 2024-02-02 1 site Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Active, not recruiting NCT NCT06577025

    A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 43 participants Est. completion 2030-09-30 16 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT06581848

    Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).

    Pfizer 150 participants Est. completion 2030-01-31 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT06629818

    Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)

    Not yet reported Peking Union Medical College Hospital 36 participants Est. completion 2027-03-14 1 site Stand-alone
    Other conditions: Light Chain (AL) Amyloidosis
    View official trial listing →
  • Not yet recruiting NCT NCT06663943

    A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.

    Not yet reported, Not yet reported Chao Ji 100 participants Est. completion 2026-11-01
    Other conditions: Pemphigus Disease, Pemphigus Vulgaris (PV)
    View official trial listing →
  • Not yet recruiting NCT NCT06742138

    To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma

    Not yet reported Qilu Pharmaceutical Co., Ltd. 284 participants Est. completion 2028-12
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT06771180

    Dara-BCD for Rare MGRS

    Not yet reported Peking University People's Hospital 10 participants Est. completion 2026-06-30 Stand-alone
    Other conditions: Monoclonal Gammopathy of Renal Significance (MGRS)
    View official trial listing →
  • Active, not recruiting NCT NCT06868654

    China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

    Not yet reported GlaxoSmithKline 72 participants Est. completion 2028-06-30 11 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT06868667

    Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

    Not yet reported GlaxoSmithKline 24 participants Est. completion 2028-06-30 16 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT06895512

    A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

    Not yet reported Shanghai Henlius Biotech 386 participants Est. completion 2027-07 1 site
    Other conditions: Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT06913192

    Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma

    Not yet reported Xuzhou Medical University 50 participants Est. completion 2028-02-28 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT06931704

    Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)

    Not yet reported Nantes University Hospital 176 participants Est. completion 2031-11-30 36 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07015021

    The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients

    Not yet reported The First Affiliated Hospital of Soochow University 72 participants Est. completion 2026-09-30 Stand-alone
    Other conditions: Multiple Myeloma, Carfilzomib, Daratumumab, Pomalidomide
    View official trial listing →
  • Not yet recruiting NCT NCT07026604

    Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study

    Not yet reported Beijing Tiantan Hospital 10 participants Est. completion 2026-11-01 1 site Stand-alone
    Other conditions: Cavernous Malformation, Cerebral
    View official trial listing →
  • Not yet recruiting NCT NCT07029776

    MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma

    Not yet reported University of Arkansas 50 participants Est. completion 2032-04-01 1 site Stand-alone
    Other conditions: Multiple Myeloma (MM)
    View official trial listing →
  • Not yet recruiting NCT NCT07072585

    Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

    Not yet reported, Not yet reported Children's Oncology Group 1708 participants Est. completion 2035-09-01 Stand-alone
    Other conditions: Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma, T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT07082270

    Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

    Not yet reported Roswell Park Cancer Institute Est. completion 2028-02-01 1 site Stand-alone
    Other conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07090954

    A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma

    Not yet reported, Not yet reported Genrix (Shanghai) Biopharmaceutical Co., Ltd. 32 participants Est. completion 2030-01-31 2 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07110662

    New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.

    Not yet reported, Not yet reported Hospices Civils de Lyon 9 participants Est. completion 2029-04-29 1 site Stand-alone
    Other conditions: Toxic Epidermal Necrolysis, Immunotherapy, Cutaneous Adverse Drug Reactions (CADR)
    View official trial listing →
  • Not yet recruiting NCT NCT07191379

    Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma

    Not yet reported Odense University Hospital 50 participants Est. completion 2028-01-01 Stand-alone
    Other conditions: Multiple Myeloma in Relapse
    View official trial listing →
  • Not yet recruiting NCT NCT07221032

    FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma

    Not yet reported Medical College of Wisconsin 12 participants Est. completion 2030-03 1 site Stand-alone
    Other conditions: Relapse Multiple Myeloma, Refractory Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07247097

    ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

    Not yet reported Massachusetts General Hospital 160 participants Est. completion 2035-12-01 3 sites Stand-alone
    Other conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
    View official trial listing →
  • Active, not recruiting NCT NCT07274462

    DARA-MVI Study (Daratumumab for Microvascular Inflammation in Kidney Transplantation)

    Not yet reported University Hospital, Martin 20 participants Est. completion 2027-09-30 1 site Stand-alone
    Other conditions: Microvascular Inflammation - MVI in Kindey Transplant Recipients
    View official trial listing →
  • Not yet recruiting NCT NCT07287228

    The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia

    Not yet reported, Not yet reported Institute of Hematology & Blood Diseases Hospital, China 37 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: Aplastic Anemia, Refractory, Relapse
    View official trial listing →
  • Not yet recruiting NCT NCT07400744

    A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects

    Not yet reported Qilu Pharmaceutical Co., Ltd. 102 participants Est. completion 2026-10
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT07428369

    A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)

    Not yet reported, Not yet reported Regeneron Pharmaceuticals Est. completion 2038-05-21
    Other conditions: Multiple Myeloma (MM)
    View official trial listing →
  • Not yet recruiting NCT NCT07532473

    REal World MAIA UK OutcomEs

    The Royal Wolverhampton Hospitals NHS Trust 300 participants Est. completion 2028-07 1 site
    Other conditions: Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07665450

    A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

    Not yet reported Janssen Research & Development, LLC 1000 participants Est. completion 2035-02-02 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07671287

    GMMG-HD11/DSMM XXI/64007957MMY3010

    Not yet reported University of Heidelberg Medical Center 399 participants Est. completion 2033-01-30 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT07689006

    Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens

    Bristol-Myers Squibb 341 participants Est. completion 2025-03-28 1 site
    Other conditions: Relapsed/Refractory Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07709715

    A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis

    Not yet reported Nexcella Inc. 260 participants Est. completion 2032-12
    Other conditions: Light Chain (AL) Amyloidosis
    View official trial listing →
  • Not yet recruiting NCT NCT07718308

    CD38 mAb Induction + Azathioprine Maintenance for Chronic Active AMR in Kidney Transplant Recipients

    Not yet reported wujianyong 20 participants Est. completion 2028-03-15
    Other conditions: Kidney Transplantation, Antibody-mediated Rejection
    View official trial listing →
  • Not yet recruiting NCT NCT07721350

    Prospective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion System

    Not yet reported Hospices Civils de Lyon 100 participants Est. completion 2027-05 1 site Stand-alone
    Other conditions: Multiple Myeloma or Amyloidosis
    View official trial listing →
  • Not yet recruiting NCT NCT07728188

    A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

    Not yet reported AbbVie 520 participants Est. completion 2033-02 66 sites
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07740486

    A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease

    Not yet reported Polish Myeloma Consortium 248 participants Est. completion 2033-04
    Other conditions: Multiple Myeloma (MM)
    View official trial listing →
  • Not yet recruiting NCT NCT07743957

    Selinexor, Daratumumab, and Dexamethasone (XDd) for Light-Chain Cardiac Amyloidosis

    Not yet reported Beijing Anzhen Hospital 63 participants Est. completion 2028-06-01 Stand-alone
    Other conditions: Light-chain Cardiac Amyloidosis
    View official trial listing →
  • Not yet recruiting NCT NCT07764861

    A Open-Label Phase in Participants With Multiple Myeloma

    Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 120 participants Est. completion 2031-06-30 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07793422

    Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis

    Not yet reported AbbVie 370 participants Est. completion 2034-12
    Other conditions: Amyloid Light Chain (AL) Amyloidosis
    View official trial listing →
  • Not yet recruiting NCT NCT07830485

    CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 24 participants Est. completion 2031-04-30 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Daratumumab, Darzalex Faspro, DARZALEX, Darzalex IV

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.